Treatment of inflammatory diseases with a monoclonal antibody to intercellular adhesion molecule 1.
A mouse monoclonal antibody to intercellular adhesion molecule 1 (ICAM-1) has been evaluated in multiple animal models of inflammation as well as in the clinic. Anti-ICAM-1 has been found to protect against allograft rejection and ischaemia/reperfusion injury in non-human primates and rabbits. In open-label phase I-II studies, anti-ICAM-1 appears to have prolonged kidney allograft survival when used as induction therapy in conjunction with traditional triple immunosuppressive therapy. Anti-ICAM-1 has shown beneficial effects in the treatment of rheumatoid arthritis when given for five days. Most patients receiving anti-ICAM-1 made antibodies to the mouse immunoglobulin.
Rothlein
R
R
Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT 06877, USA.
Jaeger
J R
JR
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D004195:Disease Models, Animal; D006801:Humans; D007249:Inflammation / Q000188:drug therapy*; D018799:Intercellular Adhesion Molecule-1 / Q000276:immunology*
D000911:Antibodies, Monoclonal; D018799:Intercellular Adhesion Molecule-1